China · Delayed Price · Currency is CNY Daan Gene Statistics
Total Valuation
Daan Gene has a market cap or net worth of CNY 9.42 billion. The enterprise value is 8.67 billion.
| Market Cap | 9.42B |
| Enterprise Value | 8.67B |
Important Dates
The next estimated earnings date is Friday, August 28, 2026.
| Earnings Date | Aug 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Daan Gene has 1.40 billion shares outstanding. The number of shares has increased by 2.97% in one year.
| Current Share Class | 1.40B |
| Shares Outstanding | 1.40B |
| Shares Change (YoY) | +2.97% |
| Shares Change (QoQ) | +2.14% |
| Owned by Insiders (%) | 2.02% |
| Owned by Institutions (%) | 7.23% |
| Float | 931.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.76 |
| PB Ratio | 1.30 |
| P/TBV Ratio | 1.42 |
| P/FCF Ratio | 98.62 |
| P/OCF Ratio | 30.32 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.68 |
| EV / Sales | 11.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 90.75 |
Financial Position
The company has a current ratio of 2.98, with a Debt / Equity ratio of 0.02.
| Current Ratio | 2.98 |
| Quick Ratio | 1.97 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.29 |
| Interest Coverage | -119.94 |
Financial Efficiency
Return on equity (ROE) is -12.03% and return on invested capital (ROIC) is -7.91%.
| Return on Equity (ROE) | -12.03% |
| Return on Assets (ROA) | -3.41% |
| Return on Invested Capital (ROIC) | -7.91% |
| Return on Capital Employed (ROCE) | -6.57% |
| Weighted Average Cost of Capital (WACC) | 5.84% |
| Revenue Per Employee | 426,569 |
| Profits Per Employee | -517,606 |
| Employee Count | 1,730 |
| Asset Turnover | 0.08 |
| Inventory Turnover | 3.75 |
Taxes
| Income Tax | -20.68M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.36% in the last 52 weeks. The beta is 0.30, so Daan Gene's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +10.36% |
| 50-Day Moving Average | 6.20 |
| 200-Day Moving Average | 6.42 |
| Relative Strength Index (RSI) | 53.36 |
| Average Volume (20 Days) | 106,525,337 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daan Gene had revenue of CNY 737.96 million and -895.46 million in losses. Loss per share was -0.63.
| Revenue | 737.96M |
| Gross Profit | 82.78M |
| Operating Income | -485.69M |
| Pretax Income | -950.66M |
| Net Income | -895.46M |
| EBITDA | -213.36M |
| EBIT | -485.69M |
| Loss Per Share | -0.63 |
Balance Sheet
The company has 1.10 billion in cash and 123.29 million in debt, with a net cash position of 979.10 million or 0.70 per share.
| Cash & Cash Equivalents | 1.10B |
| Total Debt | 123.29M |
| Net Cash | 979.10M |
| Net Cash Per Share | 0.70 |
| Equity (Book Value) | 7.27B |
| Book Value Per Share | 5.02 |
| Working Capital | 1.86B |
Cash Flow
In the last 12 months, operating cash flow was 310.55 million and capital expenditures -215.06 million, giving a free cash flow of 95.49 million.
| Operating Cash Flow | 310.55M |
| Capital Expenditures | -215.06M |
| Depreciation & Amortization | 272.33M |
| Net Borrowing | 6.72M |
| Free Cash Flow | 95.49M |
| FCF Per Share | 0.07 |
Margins
Gross margin is 11.22%, with operating and profit margins of -65.81% and -121.34%.
| Gross Margin | 11.22% |
| Operating Margin | -65.81% |
| Pretax Margin | -128.82% |
| Profit Margin | -121.34% |
| EBITDA Margin | -28.91% |
| EBIT Margin | -65.81% |
| FCF Margin | 12.94% |
Dividends & Yields
Daan Gene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.97% |
| Shareholder Yield | -2.97% |
| Earnings Yield | -9.51% |
| FCF Yield | 1.01% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 19, 2021. It was a forward split with a ratio of 1.6.
| Last Split Date | May 19, 2021 |
| Split Type | Forward |
| Split Ratio | 1.6 |
Scores
Daan Gene has an Altman Z-Score of 5.99 and a Piotroski F-Score of 3.
| Altman Z-Score | 5.99 |
| Piotroski F-Score | 3 |